Cassava Sciences (SAVA)
(Delayed Data from NSDQ)
$22.34 USD
+0.61 (2.81%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $22.33 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$22.34 USD
+0.61 (2.81%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $22.33 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Zacks News
Cassava (SAVA) Down as Quanterix Issues Statement on AD Study
by Zacks Equity Research
Cassava (SAVA) tanks yet again after Quanterix stated that it did not interpret the test results or prepare the data charts presented by the former.
Cassava (SAVA) Responds to Charges Against its Integrity in AD Study
by Zacks Equity Research
Cassava (SAVA) plunges following charges against its scientific integrity in developing a drug for Alzheimer's disease. The company responds to the same.
Cassava Sciences (SAVA) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors will be keen on updates from on its lead candidate, sumifilam, for Alzheimer's disease when Cassava (SAVA) reports Q2 results.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Biotech Stock Roundup: BIIB's AD Drug Update, CVAC's Decline on Vaccine Data & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline updates from Biogen (BIIB) and CureVac (CVAC), among others.
Cassava (SAVA) Stock Up on Alzheimer's Candidate Update
by Zacks Equity Research
Cassava Sciences' (SAVA) completes enrollment in its open-label study on simufilam. It plans to begin two pivotal phase III studies on simufilam in the second half of 2021.
Cassava Sciences (SAVA) is Overbought: Is A Drop Coming?
by Zacks Equity Research
Cassava Sciences (SAVA) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed at $79.65 in the latest trading session, marking a +1.34% move from the prior day.
Urban Outfitters, Travelzoo, Eli Lilly, Cassava Sciences and Annovis Bio highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Urban Outfitters, Travelzoo, Eli Lilly, Cassava Sciences and Annovis Bio highlighted as Zacks Bull and Bear of the Day
3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug
by Kinjel Shah
FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.
Are Options Traders Betting on a Big Move in Cassava Sciences (SAVA) Stock?
by Aditi Saraogi
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
Alzheimer's Disease: 5 Stocks on Biotech Radars
by Kevin Cook
While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $34.85, marking a -0.68% move from the previous day.
Has Cassava Sciences (SAVA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (SAVA) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Denbury, Riot Blockchain, Marathon Digital Holdings, Silvergate Capital and Cassava Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Denbury, Riot Blockchain, Marathon Digital Holdings, Silvergate Capital and Cassava Sciences
A Year Into the COVID-19 Pandemic: 5 Stock Winners
by Sweta Killa
Though the U.S. economy is far from pre-pandemic levels, it has shown solid improvement. Meanwhile, the stock market has strongly bounced back and reached new milestones.
Cassava Sciences (SAVA) Up More Than 600% YTD: Here's Why
by Zacks Equity Research
Cassava Sciences (SAVA) is progressing well with development of its Alzheimer's disease candidate, simufilam.
Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (SAVA) Outperforming Other Medical Stocks This Year?
ChemoCentryx (CCXI) Q4 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the fourth quarter and misses on sales.
Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid
by Zacks Equity Research
Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.
Implied Volatility Surging for Cassava Sciences (SAVA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
United Therapeutics (UTHR) Q4 Earnings Miss, Sales Beat
by Zacks Equity Research
United Therapeutics' (UTHR) fourth-quarter earnings miss estimates while sales beat the same. Higher sales of Orenitram, Remodulin and Tyvaso offset lower sales of Unituxin and Adcirca.
Jazz Pharma (JAZZ) Q4 Earnings Miss, 2021 Sales View Dull
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports mixed fourth-quarter 2020 results as earnings miss estimates while sales beat the same. Shares down.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $52.37, moving -1.23% from the previous trading session.
Cassava Sciences (SAVA) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cassava Sciences (SAVA) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.